Phase 3 trial shows personalized cancer vaccine cuts recurrence risk, raising access questions
A Phase 3 study presented at ESMO found the neoantigen-based vaccine intismeran autogene reduced cancer recurrence or death by 42% versus pembrolizumab alone, prompting debate on how to speed patient access.
At the European Society for Medical Oncology Congress, investigators unveiled that the personalized vaccine intismeran autogene achieved a 42% reduction in recurrence or death versus pembrolizumab in a Phase 3 trial, marking the first successful neoantigen-mRNA cancer therapy at this stage. The result confirms the therapeutic potential of individualized vaccines and shifts the conversation toward delivery challenges. Current regulatory routes, built for uniform drugs, force narrow indications and inflate costs, while the complex manufacturing chain involves multiple parties with no single accountable entity.
A forthcoming $200 million Therapeutic Cancer Vaccines Initiative, backed by the National Cancer Institute and the Foundation for the NIH, seeks to create trial networks, data standards, and infrastructure to accelerate evidence generation. Proponents argue that AI can trim costs across sequencing, design, and quality control, and that redefining the vaccine as an integrated care package rather than a vial could improve affordability.
Payers view the vaccines as costly prevention, raising coverage hurdles, but long-term savings from avoided metastatic disease may justify outcomes-based contracts. Stakeholders call for faster guideline updates and coordinated evaluation frameworks to ensure patients benefit promptly.
Why it matters
The trial proves personalized cancer vaccines can work, but without new delivery and payment models many patients may never receive them.
In this story
